한빛사논문
Heung Jin Jeon a†, Daejin Lim b†, EunA So c, Solbi Kim d, Jae-Ho Jeong c, Miryoung Song e, Hyo-Jin Lee a,d,f
aInfection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, Republic of Korea
bDivision of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea
cDepartment of Microbiology, Chonnam National University Medical School, Gwangju, Republic of Korea
dDepartment of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea
eDepartment of Bioscience and Biotechnology, Hankuk University of Foreign Studies, Yongin, Republic of Korea
fDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea
†These authors made equal contributions to this journal.
Corresponding authors : Jae-Ho Jeong, Miryoung Song, Hyo-Jin Lee
Abstract
Combination therapy with checkpoint inhibitors blocks inhibitory immune cell signaling and improves clinical responses to anticancer treatments. However, continued development of innovative and controllable delivery systems for immune-stimulating agents is necessary to optimize clinical responses. Herein, we engineered Salmonella to deliver recombinant granulocyte macrophage colony stimulating factor (GM-CSF) in a controllable manner for combination treatment with a programmed death-ligand 1 (PD-L1) inhibitor. The engineered Salmonella enabled delivery of recombinant GM-CSF into mouse tumors, activating recruitment of immune cells, such as M1-polarized macrophages, dendritic cells, and CD8+ T cells. Combination treatment with the PD-L1 inhibitor and engineered Salmonella increased the survival rate of tumor-bearing mice by 25%. New tumor growth was strongly suppressed, and visible tumors disappeared at 120 days post-infection (dpi) in mice rechallenged with additional tumor implantation at 100 dpi. The number of memory T cells increased >2-fold in tumor-rechallenged mice. Our findings demonstrate superiority of the engineered Salmonella as a cancer therapeutic agent with precise targeting ability, immune-boosting activity, and ease of combination with other therapeutics.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 논문보기